Brind.

FDA approved LOQTORZI treatment for NPC, following findings that CHS-114 depletes immunosuppressive Treg cells.

1 report, 1 independent Updated Aug 8

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

HCC FDA NPC

Keep exploring

The entities involved

HCC
Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
NPC
- The CCP has been reported to be exercising control over military figures and removing delegates from the NPC legislature.Fri 06:46

Coverage

Newest first; wire copies grouped

Aug 8GlobeNewswireCoherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update – LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and cas